SCHEDULE: T. Rowe Price Discloses 10.2% Stake in Avanos Medical
Beneficial Ownership Report
T. Rowe Price Investment Management, Inc. reported a 10.2% beneficial ownership stake in Avanos Medical Inc. common stock as of September 30, 2025.
Summary
- T. Rowe Price Investment Management, Inc. beneficially owns 4,713,494 shares of Avanos Medical Inc. common stock.
- This represents 10.2% of the class of securities.
- T. Rowe Price holds sole voting power over 4,683,148 shares and sole dispositive power over 4,713,494 shares.
- T. ROWE PRICE SMALL-CAP VALUE FUND, for which T. Rowe Price Investment Management, Inc. acts as investment adviser, holds 2,546,726 shares, representing 5.5% of the class.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avanos Medical Inc.
Sentiment
Score: 5
Explanation: The filing is a standard Schedule 13G amendment disclosing beneficial ownership, which is a neutral event in itself. It indicates a continued significant stake by a major institutional investor without suggesting any change in investment thesis or corporate control intent.
Positives
- A major institutional investor, T. Rowe Price Investment Management, Inc., maintains a significant beneficial ownership stake of 10.2% in Avanos Medical Inc., indicating continued investment interest.
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially reinforcing confidence in the company's stock due to a large, passive institutional holder.
- Company Management: Awareness of a significant, passive institutional shareholder.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement |
| 10/07/2025 | Date of signature for the Schedule 13G filing |
Keywords
Avanos Medical Inc., T. Rowe Price Investment Management, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.